Form 4: Corbus Pharmaceuticals CEO Sells Shares to Cover Tax Obligations

Corbus Pharmaceuticals CEO Yuval Cohen sold 7,134 shares of common stock on February 14, 2025, to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).

Summary

• On February 14, 2025, Yuval Cohen, the CEO of Corbus Pharmaceuticals Holdings, Inc., sold 7,134 shares of common stock.
• The sale was executed at a weighted average price of $8.7559 per share, with individual prices ranging from $8.30 to $9.14.
• This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 15, 2024.
• The purpose of the sale was to cover tax withholding obligations associated with the vesting and settlement of Restricted Stock Units (RSUs).
• The sale was mandated by Corbus Pharmaceuticals' policy requiring 'sell to cover' transactions for tax obligations, and does not represent a discretionary transaction by the CEO.
• Following the transaction, Cohen still beneficially owns 138,187 shares, which includes 123,561 unvested RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transaction is a routine sale of shares to cover tax obligations and does not necessarily indicate a positive or negative outlook for the company.

Industry Context

Sales of shares by company executives are common and often related to compensation and tax planning. The use of a 10b5-1 plan indicates the sale was pre-planned and not based on insider information at the time of the transaction.

Stakeholder Impact

• The sale of shares by the CEO could have a minor, temporary impact on the stock price, but is unlikely to have a significant long-term effect.

Key Dates

Keywords

Corbus Pharmaceuticals, Yuval Cohen, stock sale, Form 4, Rule 10b5-1, RSUs, tax withholding, CRBP